Press Release
<< Back
Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School
“We are pleased to have initiated COMMAND and are aggressively opening
sites worldwide,” said
During the dose escalation portion of the Phase 1/1b study, which included 6 patients, defactinib and paclitaxel were successfully combined, and one patient who was platinum resistant had a complete response by RECIST criteria. Enrollment for the expansion phase of the study continues.
“Research by
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
or defactinib, and the Company’s FAK program generally, the timeline for
clinical development and regulatory approval of the Company’s compounds,
the expected timing for the reporting of data from ongoing trials, and
the structure of the Company’s planned or pending clinical trials. The
words “anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds and
preliminary data from clinical trials may not be predictive of the
results or success of ongoing or later clinical trials, that data may
not be available when we expect it to be, that the Company will be
unable to successfully complete the clinical development of its
compounds, including defactinib, that the development of the Company’s
compounds will take longer or cost more than planned, and that the
Company’s compounds will not receive regulatory approval or become
commercially successful products. Other risks and uncertainties include
those identified under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com